Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
CX39EFWZu8N7tXV9
Listen
